ABBV Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 19%. AbbVie, Inc.'s return on equity of 144.3% beat Biogen, Inc.'s return on equity of 9.36%.

AbbVie, Inc. has a consensus price target of $244.68, signalling upside risk potential of 7.36%. On the other hand Biogen, Inc. has an analysts' consensus of $180.69 which suggests that it could grow by 3.43%. Given that AbbVie, Inc. has higher upside potential than Biogen, Inc., analysts believe AbbVie, Inc. is more attractive than Biogen, Inc..

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.87%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

AbbVie, Inc. quarterly revenues are $15.8B, which are larger than Biogen, Inc. quarterly revenues of $2.5B. AbbVie, Inc.'s net income of $178M is lower than Biogen, Inc.'s net income of $466.5M. Notably, AbbVie, Inc.'s price-to-earnings ratio is 172.60x while Biogen, Inc.'s PE ratio is 15.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.79x versus 2.65x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 39.21%. AbbVie, Inc.'s return on equity of 144.3% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

AbbVie, Inc. has a consensus price target of $244.68, signalling upside risk potential of 7.36%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 5.74%. Given that AbbVie, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe AbbVie, Inc. is more attractive than Gilead Sciences, Inc..

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.87%. Gilead Sciences, Inc. offers a yield of 2.52% to investors and pays a quarterly dividend of $0.79 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

AbbVie, Inc. quarterly revenues are $15.8B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. AbbVie, Inc.'s net income of $178M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 172.60x while Gilead Sciences, Inc.'s PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.79x versus 5.42x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 21.47%. AbbVie, Inc.'s return on equity of 144.3% beat Johnson & Johnson's return on equity of 33.27%.

AbbVie, Inc. has a consensus price target of $244.68, signalling upside risk potential of 7.36%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.71%. Given that AbbVie, Inc. has higher upside potential than Johnson & Johnson, analysts believe AbbVie, Inc. is more attractive than Johnson & Johnson.

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.87%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $15.8B, which are smaller than Johnson & Johnson quarterly revenues of $24B. AbbVie, Inc.'s net income of $178M is lower than Johnson & Johnson's net income of $5.2B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 172.60x while Johnson & Johnson's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.79x versus 5.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 1.13% compared to AbbVie, Inc.'s net margin of 31.72%. AbbVie, Inc.'s return on equity of 144.3% beat Eli Lilly & Co.'s return on equity of 106.26%.

AbbVie, Inc. has a consensus price target of $244.68, signalling upside risk potential of 7.36%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.01%. Given that AbbVie, Inc. has higher upside potential than Eli Lilly & Co., analysts believe AbbVie, Inc. is more attractive than Eli Lilly & Co..

AbbVie, Inc. has a beta of 0.358, which suggesting that the stock is 64.24% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

AbbVie, Inc. has a quarterly dividend of $1.64 per share corresponding to a yield of 2.87%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. AbbVie, Inc. pays 263.15% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie, Inc.'s is not.

AbbVie, Inc. quarterly revenues are $15.8B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. AbbVie, Inc.'s net income of $178M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, AbbVie, Inc.'s price-to-earnings ratio is 172.60x while Eli Lilly & Co.'s PE ratio is 53.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AbbVie, Inc. is 6.79x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.